Deciphering HCAR3-Ligand Recognition: Structural Insights for Lipid Metabolism Research

Study Background and Research Question

Hydroxycarboxylic acid receptors, notably HCAR2 and HCAR3, are G-protein coupled receptors (GPCRs) that play a pivotal role in sensing metabolites and regulating lipid metabolism. While HCAR2 is a validated target for dyslipidemia treatment, its activation is linked to adverse effects such as cutaneous flushing. Conversely, HCAR3 offers a promising alternative for metabolic disorder research, but its ligand binding preferences and selectivity mechanisms have remained poorly understood. The central question addressed by Ye et al. (2025) is: What structural features govern ligand recognition and selectivity in HCAR3, and how do these differ from HCAR2?

Key Innovation from the Reference Study

The study’s primary innovation lies in resolving the three-dimensional cryo-EM structures of HCAR3 in complex with four distinct agonists—compound 6O, D-phenyllactic acid, IBC293, and Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid)—as well as the HCAR2-Acifran complex. This represents the first structural elucidation of HCAR3's orthosteric binding pocket at near-atomic resolution, providing direct evidence for the molecular determinants of ligand specificity and receptor activation. The authors also correlate these structural insights with functional assays, offering a robust framework for rational design of selective hypolipidemic agents for lipid metabolism research.

Methods and Experimental Design Insights

Ye et al. employed an integrated structural biology approach to dissect ligand-receptor interactions. HCAR3-Gi and HCAR2-Gi complexes were expressed in Sf9 insect cells and purified for cryo-electron microscopy. The structures were determined at resolutions ranging from 2.72 Å to 3.31 Å, ensuring high confidence in side-chain positioning and ligand orientation. Key complexes included HCAR3 bound to Acifran (3.18 Å) and HCAR2 bound to Acifran (2.72 Å). Complementary cAMP accumulation assays in HEK-293 cells validated the functional consequences of ligand binding and selectivity.

Core Findings and Why They Matter

The resolved structures reveal that HCAR3 accommodates ligands through an orthosteric pocket characterized by two subregions, R1 and R2. The high-affinity agonist 6O fully occupies both, whereas Acifran selectively engages key residues within this site. Notably, the selectivity between HCAR3 and HCAR2 is governed by critical amino acid differences—including F107^3.32 (phenylalanine in HCAR3 vs. leucine in HCAR2)—and differences in pocket size shaped by V/L83^2.60, Y/N86^2.63, and S/W91^2.48. These substitutions modulate π–π interactions and spatial accommodation of aromatic agonists.

Functionally, the findings clarify why certain hypolipidemic agents, such as Acifran, display subtype-preferential activation, informing strategies to modulate lipid signaling pathways with reduced off-target effects. The structure-function relationship established here is especially important for metabolic disorder research, as it enables the design of compounds that selectively target HCAR3—potentially circumventing the flushing side effects associated with HCAR2 activation (reference study).

Comparison with Existing Internal Articles

Several internal resources contextualize the reference study’s advances. For example, "Structural Basis of HCAR3-Selective Agonist Recognition Revealed" summarizes how these new cryo-EM structures clarify the determinants of ligand binding specificity, laying the groundwork for rational design of hypolipidemic agents for lipid metabolism regulation. Other internal articles, such as "Acifran: Hypolipidemic Agent for Lipid Metabolism Research", highlight Acifran’s role as a benchmark tool for dissecting GPCR pathways, supported by the structural validation provided in Ye et al. The protocol-focused resource "Acifran in Lipid Metabolism Research: Protocols & Innovations" underscores the importance of high-purity, well-characterized agonists for reproducible modulation of lipid signaling pathways, which is now more achievable given the structural insights from the current study.

Limitations and Transferability

While these cryo-EM structures provide an unprecedented view of HCAR3-ligand interactions, several limitations must be acknowledged. The structural data are derived from receptor-Gi complexes in a controlled, detergent-solubilized environment, which may differ from the native membrane context. Moreover, while the functional cAMP assays confirm ligand activity, in vivo metabolic and pharmacological validation remains necessary to assess physiological relevance and therapeutic potential. Additionally, the findings are most directly transferable to studies of lipid metabolism and signaling rather than broader metabolic or non-GPCR targets.

Protocol Parameters

• HCAR3/HCAR2 complex expression: Use Sf9 cells for high-yield GPCR-Gi fusion protein production, as detailed in the reference study.
• Ligand incubation for cryo-EM: Incubate purified receptor with Acifran or other agonists at saturating concentrations to ensure full occupancy of the orthosteric pocket.
• cAMP functional assay: Employ HEK-293 cells transfected with HCAR3 or HCAR2 constructs; measure cAMP levels to quantify functional receptor activation after agonist treatment.
• Structural data validation: Deposit 3D cryo-EM maps and atomic coordinates in publicly accessible databases (e.g., EMDB, PDB) for reproducibility.
• Recommended compound handling: For Acifran, prepare stock solutions in DMSO or ethanol at <21.82 mg/ml, store at -20°C, and use solutions within a short time frame to maintain integrity (product information).

Research Support Resources

To facilitate structural and functional studies of HCAR family receptors in lipid metabolism regulation, researchers can leverage selective agonists such as Acifran (SKU B6848, (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid), available from APExBIO. This compound supports reproducible workflows for dissecting receptor-ligand interactions and lipid signaling pathway modulation. For further background, the referenced study and linked internal articles provide detailed protocols and structural context for metabolic disorder research using hypolipidemic agents.